Acquired cancer tyrosine kinase inhibitor resistance: ROS as critical determinants

作     者：Sander Bekeschus Sander Bekeschus

作者机构：ZIK plasmatisLeibniz Institute for Plasma Science and Technology(INP)Felix-Hausdorff-Str.217489 GreifswaldGermany 

出 版 物：《Signal Transduction and Targeted Therapy》 (信号转导与靶向治疗（英文）)

年 卷 期：2022年第7卷第1期

页      面：17-18页

核心收录：

学科分类：0710[理学-生物学] 1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Open Access funding enabled and organized by Projekt DEAL 

主　　题：cancer drug cycling 

摘      要：The ability of a minority of cancer cells lineages to withstand drug-induced toxicity and re-enter cell cycling in the presence of the drug has been observed for long,but the underlying mechanisms remained *** work published in Nature by Oren and colleagues used barcode lentiviral library labeling to prominently discern antioxidant profiles,among others,being the primary underlying cellular program that governs proliferation under tyrosine kinase inhibitor(TKI)drug pressure.^(1)